The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration

Jerel A. Fields, Jeff Metcalf, Cassia Overk, Anthony Adame, Brian Spencer, Wolfgang Wrasidlo, Jazmin Florio, Edward Rockenstein, Johnny Jianglin He, Eliezer Masliah

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

Despite the success of antiretroviral therapies to control systemic HIV-1 infection, the prevalence of HIV-associated neurocognitive disorders (HANDs) has not decreased among aging patients with HIV. Autophagy pathway alterations, triggered by HIV-1 proteins including gp120, Tat, and Nef, might contribute to the neurodegenerative process in aging patients with HAND. Although no treatments are currently available to manage HAND, we have previously shown that sunitinib, an anticancer drug that blocks receptor tyrosine-kinase and cyclin kinase pathways, might be of interest. Studies in cancer models suggest that sunitinib might also modulate autophagy, which is dysregulated in our models of Tat-induced neurotoxicity. We evaluated the efficacy of sunitinib to promote autophagy in the CNS and ameliorate neurodegeneration using LC3-GFP-expressing neuronal cells challenged with low concentrations of Tat and using inducible Tat transgenic mice. In neuronal cultures challenged with low levels of Tat, sunitinib increased markers of autophagy such as LC3-II and reduced p62 accumulation in a dose-dependent manner. In vivo, sunitinib treatment restored LC3-II, p62, and endophilin B1 (EndoB1) levels in doxycycline-induced Tat transgenic mice. Moreover, in these animals, sunitinib reduced the hyperactivation of CDK5, tau hyperphosphorylation, and p35 cleavage to p25. Restoration of CDK5 and autophagy were associated with reduced neurodegeneration and behavioral alterations. Alterations in autophagy in the Tat tg mice were associated with reduced levels of a CDK5 substrate, EndoB1, and levels of total EndoB1 were normalized by sunitinib treatment. We conclude that sunitinib might ameliorate Tat-mediated autophagy alterations and may decrease neurodegeneration in aging patients with HAND.

Original languageEnglish
Pages (from-to)290-303
Number of pages14
JournalJournal of NeuroVirology
Volume23
Issue number2
DOIs
StatePublished - 1 Apr 2017

Fingerprint

Autophagy
HIV-1
Pharmaceutical Preparations
HIV
Transgenic Mice
Human Immunodeficiency Virus Proteins
Drug Receptors
Cyclins
sunitinib
Doxycycline
Therapeutics
Protein-Tyrosine Kinases
HIV Infections
Phosphotransferases
Neurocognitive Disorders
Neoplasms

Keywords

  • Autophagy
  • HIV-1
  • In vivo
  • Sunitinib

Cite this

Fields, Jerel A. ; Metcalf, Jeff ; Overk, Cassia ; Adame, Anthony ; Spencer, Brian ; Wrasidlo, Wolfgang ; Florio, Jazmin ; Rockenstein, Edward ; He, Johnny Jianglin ; Masliah, Eliezer. / The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration. In: Journal of NeuroVirology. 2017 ; Vol. 23, No. 2. pp. 290-303.
@article{42208684503e422683a9dad08b93f0ba,
title = "The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration",
abstract = "Despite the success of antiretroviral therapies to control systemic HIV-1 infection, the prevalence of HIV-associated neurocognitive disorders (HANDs) has not decreased among aging patients with HIV. Autophagy pathway alterations, triggered by HIV-1 proteins including gp120, Tat, and Nef, might contribute to the neurodegenerative process in aging patients with HAND. Although no treatments are currently available to manage HAND, we have previously shown that sunitinib, an anticancer drug that blocks receptor tyrosine-kinase and cyclin kinase pathways, might be of interest. Studies in cancer models suggest that sunitinib might also modulate autophagy, which is dysregulated in our models of Tat-induced neurotoxicity. We evaluated the efficacy of sunitinib to promote autophagy in the CNS and ameliorate neurodegeneration using LC3-GFP-expressing neuronal cells challenged with low concentrations of Tat and using inducible Tat transgenic mice. In neuronal cultures challenged with low levels of Tat, sunitinib increased markers of autophagy such as LC3-II and reduced p62 accumulation in a dose-dependent manner. In vivo, sunitinib treatment restored LC3-II, p62, and endophilin B1 (EndoB1) levels in doxycycline-induced Tat transgenic mice. Moreover, in these animals, sunitinib reduced the hyperactivation of CDK5, tau hyperphosphorylation, and p35 cleavage to p25. Restoration of CDK5 and autophagy were associated with reduced neurodegeneration and behavioral alterations. Alterations in autophagy in the Tat tg mice were associated with reduced levels of a CDK5 substrate, EndoB1, and levels of total EndoB1 were normalized by sunitinib treatment. We conclude that sunitinib might ameliorate Tat-mediated autophagy alterations and may decrease neurodegeneration in aging patients with HAND.",
keywords = "Autophagy, HIV-1, In vivo, Sunitinib",
author = "Fields, {Jerel A.} and Jeff Metcalf and Cassia Overk and Anthony Adame and Brian Spencer and Wolfgang Wrasidlo and Jazmin Florio and Edward Rockenstein and He, {Johnny Jianglin} and Eliezer Masliah",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s13365-016-0502-z",
language = "English",
volume = "23",
pages = "290--303",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

Fields, JA, Metcalf, J, Overk, C, Adame, A, Spencer, B, Wrasidlo, W, Florio, J, Rockenstein, E, He, JJ & Masliah, E 2017, 'The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration', Journal of NeuroVirology, vol. 23, no. 2, pp. 290-303. https://doi.org/10.1007/s13365-016-0502-z

The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration. / Fields, Jerel A.; Metcalf, Jeff; Overk, Cassia; Adame, Anthony; Spencer, Brian; Wrasidlo, Wolfgang; Florio, Jazmin; Rockenstein, Edward; He, Johnny Jianglin; Masliah, Eliezer.

In: Journal of NeuroVirology, Vol. 23, No. 2, 01.04.2017, p. 290-303.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration

AU - Fields, Jerel A.

AU - Metcalf, Jeff

AU - Overk, Cassia

AU - Adame, Anthony

AU - Spencer, Brian

AU - Wrasidlo, Wolfgang

AU - Florio, Jazmin

AU - Rockenstein, Edward

AU - He, Johnny Jianglin

AU - Masliah, Eliezer

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Despite the success of antiretroviral therapies to control systemic HIV-1 infection, the prevalence of HIV-associated neurocognitive disorders (HANDs) has not decreased among aging patients with HIV. Autophagy pathway alterations, triggered by HIV-1 proteins including gp120, Tat, and Nef, might contribute to the neurodegenerative process in aging patients with HAND. Although no treatments are currently available to manage HAND, we have previously shown that sunitinib, an anticancer drug that blocks receptor tyrosine-kinase and cyclin kinase pathways, might be of interest. Studies in cancer models suggest that sunitinib might also modulate autophagy, which is dysregulated in our models of Tat-induced neurotoxicity. We evaluated the efficacy of sunitinib to promote autophagy in the CNS and ameliorate neurodegeneration using LC3-GFP-expressing neuronal cells challenged with low concentrations of Tat and using inducible Tat transgenic mice. In neuronal cultures challenged with low levels of Tat, sunitinib increased markers of autophagy such as LC3-II and reduced p62 accumulation in a dose-dependent manner. In vivo, sunitinib treatment restored LC3-II, p62, and endophilin B1 (EndoB1) levels in doxycycline-induced Tat transgenic mice. Moreover, in these animals, sunitinib reduced the hyperactivation of CDK5, tau hyperphosphorylation, and p35 cleavage to p25. Restoration of CDK5 and autophagy were associated with reduced neurodegeneration and behavioral alterations. Alterations in autophagy in the Tat tg mice were associated with reduced levels of a CDK5 substrate, EndoB1, and levels of total EndoB1 were normalized by sunitinib treatment. We conclude that sunitinib might ameliorate Tat-mediated autophagy alterations and may decrease neurodegeneration in aging patients with HAND.

AB - Despite the success of antiretroviral therapies to control systemic HIV-1 infection, the prevalence of HIV-associated neurocognitive disorders (HANDs) has not decreased among aging patients with HIV. Autophagy pathway alterations, triggered by HIV-1 proteins including gp120, Tat, and Nef, might contribute to the neurodegenerative process in aging patients with HAND. Although no treatments are currently available to manage HAND, we have previously shown that sunitinib, an anticancer drug that blocks receptor tyrosine-kinase and cyclin kinase pathways, might be of interest. Studies in cancer models suggest that sunitinib might also modulate autophagy, which is dysregulated in our models of Tat-induced neurotoxicity. We evaluated the efficacy of sunitinib to promote autophagy in the CNS and ameliorate neurodegeneration using LC3-GFP-expressing neuronal cells challenged with low concentrations of Tat and using inducible Tat transgenic mice. In neuronal cultures challenged with low levels of Tat, sunitinib increased markers of autophagy such as LC3-II and reduced p62 accumulation in a dose-dependent manner. In vivo, sunitinib treatment restored LC3-II, p62, and endophilin B1 (EndoB1) levels in doxycycline-induced Tat transgenic mice. Moreover, in these animals, sunitinib reduced the hyperactivation of CDK5, tau hyperphosphorylation, and p35 cleavage to p25. Restoration of CDK5 and autophagy were associated with reduced neurodegeneration and behavioral alterations. Alterations in autophagy in the Tat tg mice were associated with reduced levels of a CDK5 substrate, EndoB1, and levels of total EndoB1 were normalized by sunitinib treatment. We conclude that sunitinib might ameliorate Tat-mediated autophagy alterations and may decrease neurodegeneration in aging patients with HAND.

KW - Autophagy

KW - HIV-1

KW - In vivo

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=85009919349&partnerID=8YFLogxK

U2 - 10.1007/s13365-016-0502-z

DO - 10.1007/s13365-016-0502-z

M3 - Article

VL - 23

SP - 290

EP - 303

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 2

ER -